Corcept Therapeutics Incorporated (NASDAQ: CORT) is scheduled to reveal its financial results for the third quarter on Wednesday 30th October 2024. This disclosure will take place after market close, providing investors with significant information regarding the company's performance in the last three months period.
Financial experts on Wall Street anticipate that the organization is set to announce an estimated $0.28 profit per share for the quarter. Furthermore, the company is expected to disclose a total revenue of $171.97 million for this specific period.
Upon revisiting the corresponding quarter from the prior year, the company's earnings report demonstrated a per-share income of $0.28. This figure was attributed to the company's total revenue, which reached an impressive $123.6 million during that same period.
Wall Street analysts have offered their forecasts for the company's yearly performance, predicting a total revenue of $661.06 million. At the same time, they are expecting the company to achieve per share profit of $1.12 for the fiscal year ahead.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $0.32 | +28.0% | 163.77 M | +39.1% |
| Q1 2024 | $0.25 | +78.6% | 146.81 M | +39.0% |
| Q4 2023 | $0.28 | +100.0% | 135.41 M | +31.4% |
| Q3 2023 | $0.28 | -6.7% | 123.60 M | +21.5% |
| Q2 2023 | $0.25 | +4.2% | 117.72 M | +13.9% |
| *Growth on year-over-year basis | ||||
In addition, The firm will review the third quarter financial results on 30th October 2024 at 05:00 PM eastern time, in a conference call with public.
During Monday's trading, Corcept Therapeutics Incorporated (CORT) shares reached a low of $47.44 and a high of $49.19, along with a total volume of 682.80 thousand shares. The stock ended the regular trading session at $48.34, indicating an upturn of 2.24 percent.
